One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Journals package 3months
-
http://medilib.ir
- Duration of Time : 93 Day
Price : 100$- Special Price : 50$
Wildfires: what does the evidence say?
doi : 10.1016/S0140-6736(25)00136-9
Volume 405, Issue 10475, 25–31 January 2025, Page 273
Uveitis in juvenile idiopathic arthritis: when to stop adalimumab?
Antibody testing to predict SARS-CoV-2 risk in immunocompromised people
Durability of patient benefit from CT-guided chest pain management
Winner of 2024 Wakley–Wu Lien Teh Prize: "breaking free from the cocoon"
Leadership roles in response to mpox and Marburg virus disease outbreaks
Polio in Sudan and other conflict zones: a call for urgent support
The R21/Matrix-M malaria vaccine: questions remain – Author's reply
Undervaccination and severe COVID-19 outcomes – Authors' reply
Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial
Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study
Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland
Radiotherapy toxicities: mechanisms, management, and future directions
